Login to Your Account



Try, try, try, try, try, try, try again

Learnings aside, hope for amyloid springs eternal

By Anette Breindl
Senior Science Editor

Friday, December 22, 2017

Given the state of Alzheimer's disease (AD) drug development, one might wonder whether those engaged in it also suffer from memory loss. Targeting amyloid beta has failed in the clinic, over and over again. But both the failed agents themselves and other amyloid-targeting drugs remain in clinical trials.

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription